Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity.

La Manna, Federico; De Menna, Marta; Patel, Nikhil; Karkampouna, Sofia; De Filippo, Maria Rosaria; Klima, Irena; Kloen, Peter; Beimers, Lijkele; Thalmann, George N.; Pelger, Rob C. M.; Jacinto, Estela; Kruithof-de Julio, Marianna (2021). Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity. Frontiers in oncology, 11, p. 650623. Frontiers Research Foundation 10.3389/fonc.2021.650623

[img]
Preview
Text
Tha_Corrigendum_DualmTOR_Inhibitor_Rapalink1_Reduces_Prostate_Cancer_PatientDerived_Xenograft_Growth_and_Alters_Tumor_Heterogeneity.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (200kB) | Preview

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

La Manna, Federico; De Menna, Marta; Karkampouna, Sofia; De Filippo, Maria Rosaria; Klima, Irena; Thalmann, George and Kruithof-de Julio, Marianna

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2234-943X

Publisher:

Frontiers Research Foundation

Language:

English

Submitter:

Jeannine Wiemann

Date Deposited:

13 Oct 2021 10:14

Last Modified:

17 Oct 2021 03:09

Publisher DOI:

10.3389/fonc.2021.650623

Related URLs:

PubMed ID:

33614519

Uncontrolled Keywords:

ALDH PDX bone metastasis disulfiram mTOR prostate cancer

BORIS DOI:

10.48350/159658

URI:

https://boris.unibe.ch/id/eprint/159658

Actions (login required)

Edit item Edit item
Provide Feedback